Abstract:Alzheimer's disease (AD) has become a leading public health issue due to our nation's burgeoning aging population. These issues are further complicated by the fact that neither preventive measure and effective treatment nor definitive in vivo diagnostic tool for this burdensome disease is currently available. Genetic, biochemical, and neuropathological data argue that Abeta amyloidosis, which originates from the Abeta amyloidogenic processing of a metalloprotein-amyloid precursor protein (APP), is the key event in AD pathology. However, neurochemical factors that impact upon this age-dependent protein disorder in brain are not well recognized. Considerable evidence is mounting that dyshomeostasis of the redox-active biometals, Cu and Fe, and oxidative stress contribute to the neuropathology of Alzheimer's disease (AD). Present data suggest that metals can interact directly with Abeta peptide, the principle component of Abeta amyloid that is one of the primary lesions in AD. The binding of metals to Abeta modulates several physiochemical properties of Abeta that are thought to be central to the pathogenicity of the peptide. First, we and others have shown that metals can promote the in vitro aggregation into tinctorial and disordered protein-Abeta amyloid. Studies have confirmed that insoluble amyloid plaques in post-mortem AD brain are abnormally enriched in Cu, Fe, and Zn. Conversely, metal chelators dissolve these proteinaceous deposits from postmortem AD brain tissue and attenuate cerebral Abeta amyloid burden in APP transgenic mouse models of AD. Second, we have demonstrated that redox-active Cu(II), and to a lesser extent, Fe(III), are reduced in the presence of Abeta with concomitant production of reactive oxygen species (ROS)-hydrogen peroxide (H2O2) and hydroxyl radical (OH.). These Abeta/metal redox reactions, which are silenced by redox-inert Zn(II), but exacerbated by biological reducing agents, may lead directly to the widespread oxidation damages observed in AD brains. Moreover, studies have also shown that H2O2 mediates Abeta cellular toxicity and increases the production of both Abeta and amyloid precursor protein (APP). Third, the 5'untranslated region (5'UTR) of APP mRNA has a functional iron-response element (IRE) which is consistent with biochemical evidence that APP is redox-active metalloprotein. Hence, the redox interactions between Abeta, APP, and metals may be at the heart of a pathological positive feedback system wherein Abeta amyloidosis and oxidative stress promote each other. The emergence of redox-active metals as key players in AD pathogenesis strongly argues that amyloid-specific metal-complexing agents and antioxidants be investigated as possible disease-modifying agents for treating this horrible disease. In addition, the AD diagnosis currently relies on behavior-based tests-e.g., Mini-Mental State Examination (MMSE). However, it is not specific for AD as many factors may lead to memory impairment and cognitive failure. The only definitive diagnosis for AD is the post-mortem examination of brain tissue for cerebral Abeta amyloidosis, the neuropathological hallmark of AD (2,3). Thus, development of in vivo amyloid imaging agents can not only provide definitive AD diagnostic tools but also speed up the preclinical and clinical assessment of novel AD therapeutic agents targeting Abeta amyloid. In summary, study of AD metallobiochemistry cements a solid foundation for discovering novel theranostic agents of AD.

Label-Free In Situ Chemical Characterization of Amyloid Plaques in Human Brain Tissues

Multielement analysis of swiss mice brains with Alzheimer's disease induced by beta amyloid oligomers using a portable total reflection X- ray fluorescence system

Metallobiochemistry of Alzheimer's Disease and Its Theranostic Agent Development.

Quantitative chemical imaging of amyloid-β plaques with Raman micro-spectroscopy in human Alzheimer's diseased brains

Chemical imaging signatures delineate heterogeneous amyloid plaque populations across the Alzheimers disease spectrum

High Contrast and Resolution Labeling of Amyloid Plaques in Tissue Sections from APP-PS1 Mice and Humans with Alzheimer's Disease with the Zinc Chelator HQ-O: Practical and Theoretical Considerations

Isotope Encoded Chemical Imaging Identifies Amyloid Plaque Age Dependent Structural Maturation, Synaptic Loss, and Increased Toxicity

Spatial Neurolipidomics at the Single Amyloid-β Plaque Level in Postmortem Human Alzheimer’s Disease Brain

Metals in Imaging of Alzheimer’s Disease

Preliminary Studies of a Novel Bifunctional Metal Chelator Targeting Alzheimer's Amyloidogenesis

Label-free imaging of amyloid plaques in Alzheimer's disease with stimulated Raman scattering microscopy.

Metal imaging in neurodegenerative diseases

Unlocking the Molecular Variations of a Micron-Scale Amyloid Plaque in an Early Stage Alzheimer’s Disease by a Cellular-Resolution Mass Spectrometry Imaging Platform

In Vivo Biosynthesized Zinc and Iron Oxide Nanoclusters for High Spatiotemporal Dual-Modality Bioimaging of Alzheimer's Disease.

Study of Specially Labeling Amyloid Plaques in Vivo in Alzheimer Transgenic Mice with Targeted Magnetic Nano-Iron Contrast Agent

Label-Free SERS Strategy for in Situ Monitoring and Real-Time Imaging of Aβ Aggregation Process in Live Neurons and Brain Tissues.

Proteomic characterization of postmortem amyloid plaques isolated by laser capture microdissection.

Mapping cellular stress and lipid dysregulation in Alzheimer-related progressive neurodegeneration using label-free Raman microscopy

Laser ablation-inductively coupled plasma-mass spectrometry imaging of white and gray matter iron distribution in Alzheimer's disease frontal cortex

Novel Drug Targets Based on Metallobiology of Alzheimer's Disease

Multimodal microscopy for characterization of amyloid-${\unicode[Times]{x3B2}}$ plaques biomarkers in animal model of Alzheimer's disease